Search results
Results From The WOW.Com Content Network
Mylan’s second recall of Insulin Glargine this year. Mylan Pharmaceuticals recalled one batch of Insulin Glargine Injection, 100 units/mL (U-100), 3 mL prefilled pens, which are sold in cartons ...
In 2018, Amneal Pharmaceuticals LLC merged with Impax Laboratories, Inc. to form Amneal Pharmaceuticals, Inc. The FTC described the merger as having a value of US$1.45 billion, and required the companies to divest several marketed products and development projects as a condition of the approval. [16]
It’s estimated that nearly 5% of Americans above the age of 12 live with hypothyroidism, a condition that occurs when the body experiences a deficit of thyroid hormone.. The thyroid gland ...
Mylan N.V. was a global generic and specialty pharmaceuticals company. In November 2020, Mylan merged with Upjohn , Pfizer 's off-patent medicine division, to form Viatris . [ 2 ] Previously, the company was domiciled in the Netherlands , with principal executive offices in Hatfield, Hertfordshire , UK [ 3 ] and a "Global Center" in Canonsburg ...
The investigation against Mylan was related to the pricing and marketing of its generic doxycycline antibiotic that is used to treat bacterial infections such as acne, pneumonia, lyme disease ...
There was a second issue that levothyroxine preparations were not properly stable, resulting in recalls. The FDA required a NDA (new drug application) to resolve the second of these issues, which led to synthroid (amongst others) being reformulated to improve its stability.
Viatris Inc's (NASDAQ: VTRS) Mylan is voluntarily recalling one lot of Octreotide Acetate Injection, 500 mcg/mL, packaged in a carton of ten 1mL syringes due to a product complaint of the presence ...
Drugs or medicines may be withdrawn from commercial markets because of risks to patients, but also because of commercial reasons (e.g. lack of demand and relatively high production costs).